- The Digital Doc: Exploring Health Tech Innovation
- Posts
- The The Digital Doc: Exploring Health Tech Innovation
The The Digital Doc: Exploring Health Tech Innovation
DEA Extends Telemedicine Flexibilities for Prescribing of Controlled Medications
Drug Enforcement Administration (DEA) released a second temporary rule extending the COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
Email Dr. Erkeda for consulting & friendly PC partnerships @ [email protected]
Here are the details:
DEA's Second Temporary Rule on COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
Overview:
On October 6, 2023, DEA announced a second temporary rule extending COVID-19 telemedicine flexibilities.
Without this extension, the flexibilities would expire on November 11, 2023 for newly established practitioner-patient relationships.
Flexibilities initially introduced in March 2020 are now extended until December 31, 2024.
Key Provisions:
Scope of DEA waivers under this rule:
Extends the "full set" of telemedicine flexibilities for prescription of controlled medications.
Refers to two DEA letters from March 2020, detailing:
Waivers on DEA registrations in individual states.
Waivers on in-person evaluation requirements for online prescriptions.
Flexibility to prescribe buprenorphine to patients with opioid use disorder via telephone without an in-person exam.
Foley confirmed with DEA's Scott Brinks that the single-state DEA registration policy from the March 25, 2020 letter is extended.
Time Period of the Second Temporary Rule:
Flexibilities extended through December 31, 2024.
Removed distinction between new and previously seen patients in the initial extension. All DEA-registered practitioners can now prescribe schedule II-V controlled medications via telemedicine through the end of 2024.
Future DEA Rulemaking:
DEA plans to introduce new standards by the Fall of 2024.
Indicates a possible need for a third extension before new rules come into effect.
Conclusion:
Extension benefits telemedicine companies, allowing them to plan until the end of 2024.
It's uncertain what the DEA's 2024 proposal will entail regarding special telemedicine registration.
Ongoing monitoring is recommended for further updates.
How can Dr. Erkeda help your team:
Available to serve as healthcare tech consultant- specializes in workflow optimization, strategy, tech optimization, health equity integration, and more
Available to provide workshops and talks on leadership, overcoming obstacles, telehealth, and healthtech
Licensed in 48 states and DC with extensive leadership experience in telehealth- Able to serve as Friendly PC owner for startups
Email [email protected] with inquiries
Dr Erkeda also hosts leadership and telehealth workshops/ lunch & learns